ASX Announcement

16 July 2020

Antisense Therapeutics to Participate at the 2020 Virtual Annual Conference Hosted by Parent Project Muscular Dystrophy

Antisense Therapeutics [ASX:ANP | US OTC:ATHJY], (the Company) an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases, including Duchenne muscular dystrophy (DMD) is pleased to advise that Gil Price, MD, US-based Medical Director, will participate on the "In the Pipeline: Reducing Inflammation" panel at 7:00pm EDT on July 22, 2020 (9:00am AEST on July 23, 2020) during the 2020 Virtual Conference hosted by Parent Project Muscular Dystrophy (PPMD). To access the live streaming or recording of the conference, people can register for free on PPMD's website by click here. Registration also provides you with access to PPMD's Virtual Hub and On-Demand Library. Otherwise, all presentations from the Virtual Conference will be available for download within a couple of weeks after the Conference.

The Company recently released positive data from its Phase II clinical trial of ATL1102 in nine non-ambulant boys with DMD. The trial was an open label six-month dosing trial of ATL1102 that was conducted at the neuromuscular centre of the Royal Children's Hospital in Melbourne, Australia. ATL1102 met the primary endpoint of the study with confirmation of the drug's safety and tolerability. ATL1102 also demonstrated strong effects on secondary endpoints including activity on the targeted CD49d immune cells consistent with the drug's proposed mechanism of action and outcomes on disease progression parameters that exceeded the Company's expectations with improvement or stabilization across different measures of muscle function and strength. The positive effects on disease progression were further supported by MRI data that suggested a stabilization in the percentage of fat fraction in the muscles and preservation of functional muscle mass. The Company is in advanced planning for the conduct of a Phase IIb clinical trial in non-ambulant boys with DMD. For more information please contact:

Antisense Therapeutics
Mark Diamond
CEO & Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
+61 423 500 233
gkoutchin@xecpartners.com.au

US Enquiries
Erin Cox
IR & Patient Advocacy
+1 206 579 3457
erin.cox@antisense.com.au

This announcement has been authorised for release by the Board

About Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne—our mission is to end Duchenne. We demand optimal care standards and strive to ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won three FDA approvals. Join our fight against Duchenne at EndDuchenne.org and follow PPMD on Facebook, Twitter, Instagram, and YouTube.

About Antisense Therapeutics

Antisense Therapeutics is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.